Phenom Named Strategic Leader in 2024 Fosway 9-Grid™ for Talent & People Success
10.10.2024 11:30:00 CEST | Business Wire | Press release
Positioning Recognises Phenom’s Impact on Helping Europe’s Largest Companies Solve HR’s Biggest Talent Management Challenges
Phenom has been named a Strategic Leader in the 2024 Fosway 9-Grid™ for Talent and People Success, a testament to the value delivered by the AI-powered Phenom Intelligent Talent Experience platform, which makes new employees productive faster, enhances development and increases retention.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241010930504/en/

Phenom has been named a Strategic Leader in the 2024 Fosway 9-Grid™ for Talent and People Success, a testament to the value delivered by the AI-powered Phenom Intelligent Talent Experience platform, which makes new employees productive faster, enhances development and increases retention. (Graphic: Business Wire)
Fosway Group identifies Strategic Leaders as companies that provide a rich suite of capability across a broad scope of features and have the sophistication to consistently meet the needs of complex enterprise-scale customers. Strategic Leaders are also recognised by Fosway Group for having strong market performance and customer advocacy; as a result, they are frequently selected by such organisations and consistently meet their needs.
From labour shortages to changing skills and emerging technologies, the European job market continues to transform. To navigate this, talent management professionals, HR leaders and HRIT teams must collaborate to make new employees productive from day one, provide continued development opportunities, identify and fill skills gaps and encourage long-term retention.
“As European organisations wrestle with how they become more skills-based, they have been looking at how their tech stack solves that problem,” said David Wilson, CEO and founder of Fosway Group. “With their roots in skill-based hiring and their growing specialist capability around internal mobility and skills intelligence, Phenom has been well placed to provide a springboard to those answers for enterprise buyers. And their growing service and platform maturity has been pivotal in making them a Strategic Leader for talent experience on the Fosway 9-Grid™ this year.”
Phenom’s solution for talent and people success centers around delivering hyper-personalised experiences for employees, their managers and talent management. These experiences are enhanced with X+, Phenom’s Generative AI that is purpose-built for HR, to support key areas including:
- Pre-boarding: Provides a streamlined, transparent and easy experience that makes a lasting positive impact for new employees.
- Onboarding: Shortens time to productivity for new employees and automates tedious, manual tasks for HR teams.
- Talent Marketplace: Gives employees visibility to internal job and growth opportunities, as well as refers quality talent for critical roles.
- Career Pathing: Helps employees discover their next internal career move and the skills needed to get there. X+ provides an always on career coach that responds to their questions with personalised development plans.
- Cross-boarding: Supports employee transitions to new positions and teams.
- Workforce Intelligence: Identifies skill and competency gaps and insights within each department and at the enterprise level.
- Learning and Development: Educates internal talent with personalised courses to support upskilling and reskilling based on their projected career paths.
- Mentoring: Empowers and supports employees throughout their career journey by connecting them with best-fit mentors.
- Gigs: Provides real-world experience through short-term work and project-based tasks allowing employees to develop their skills.
- Employee Resource Groups: Fosters engagement, community and a sense of belonging.
- Offboarding: Streamlines experiences for employees leaving the organisation.
“Phenom’s positioning is a testament to our ongoing innovation and helping European organisations embrace a skills-based approach to talent management, growth and retention,” said John Deal, Sr. Director, Product Marketing at Phenom. “As Europe contends with an evolving workforce landscape, it has never been more critical to leverage intelligence to enable smarter and more impactful career development, upskilling and workforce planning decisions.”
Phenom’s placement also complements the company’s four-year positioning as a Strategic Leader in the Fosway 9-Grid™ for Talent Acquisition, showcasing the end-to-end benefits of using its full Intelligent Talent Experience platform. Over 700 global and diverse companies are using the Phenom platform to help:
- Candidates find and choose the right job faster.
- Employees develop their skills and evolve.
- Recruiters become wildly productive.
- Talent marketers engage with extreme efficiency.
- Talent leaders optimise hiring processes.
- Managers build stronger-performing teams.
- HR aligns employee development with company goals.
- HRIT easily integrates existing HR tech to create a holistic infrastructure.
See why Phenom continues to be recognised as industry leading, book a demo.
Click here for a personalised demo of Phenom’s Workforce Intelligence solution to learn more about how to set your employees up for career success.
About Phenom
Phenom has a purpose of helping a billion people find the right work. Through AI-powered talent experiences, employers use Phenom to hire and onboard employees faster, develop them to their full potential, and retain them longer. The Phenom Intelligent Talent Experience platform seamlessly connects candidates, employees, recruiters, talent marketers, talent leaders, hiring managers, HR and HRIT — empowering diverse and global enterprises with innovative products including Phenom X+ Generative AI, Career Site, Chatbot, CMS, Talent CRM, X+ Screening, Automated Interview Scheduling, Interview Intelligence, Talent Experience Engine, Campaigns, University Recruiting, Contingent Talent Hiring, Onboarding, Talent Marketplace, Workforce Intelligence, Career Pathing, Gigs, Mentoring, and Referrals.
Phenom has earned accolades including: Inc. 5000’s fastest-growing companies (5 consecutive years), Deloitte Technology's Fast 500 (4 consecutive years), five Brandon Hall ‘Excellence in Technology’ awards including Gold for ‘Best Advance in AI for Business Impact,’ Business Intelligence Group's Artificial Intelligence Excellence Awards (3 consecutive years), and a regional Timmy Award for launching and optimising HelpOneBillion.com (2020).
Headquartered in Greater Philadelphia, Phenom also has offices in India, Israel, the Netherlands, Germany and the United Kingdom.
For more information, please visit www.phenom.com. Connect with Phenom on LinkedIn, X, Facebook, YouTube and Instagram.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241010930504/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom